Abstract:The precursor of recombinant human insulin is also called recombinant proinsulin. It is a fusion protein containing protection peptide and insulin. The protection peptide contains 55 amino acids (48 amino acids from human growth hormone, and a connecting peptide containing Arg-residues) and can effectively improve protein stability and expression efficiency [1]. However, in clinical trials the presence of proinsulin in the insulin final products was found to have a negative effect on the heart, leading to an increased incidence of myocardial infarction [2–6]. More importantly, recombinant proinsulin is a heterologous protein. Therefore, the removal of the recombinant proinsulin in the final product of insulin is vital, and the effectiveness of its removal should be analyzed by appropriate methods. In this study, we prepared specific monoclonal and polyclonal antibodies against proinsulin and established enzyme-linked immunosorbent assay (ELISA) for the detection of the residual precursor in the insulin production. Three adult female BALB/c mice were intraperitoneally injected with 55-peptide as an antigen. Each mouse was injected with 100 mg antigen mixed with complete Freund’s adjuvant (Sigma, St Louis, USA) the first time, and then boosted with 50 mg antigen mixed with incomplete Freund’s adjuvant for three times. The injection interval was 2 weeks. After four immunizations, spleen cells were fused with SP2/0 myeloma cells and the hybridoma cells were selected by growing in HAT (hypoxanthine, aminopterin, and thymidine) medium. Monoclonal cell lines were screened by the limiting dilution method. To obtain a large amount of antibodies, the hybridoma cells were injected into the peritoneal cavity of mice, and antibody-rich ascites was collected. The antibodies were purified by protein-G Sepharose (GE Healthcare, Wisconsin, USA). The titer of anti-55-peptide monoclonal antibody (mAb) was determined by indirect ELISA. New Zealand white rabbits were immunized with the purified recombinant proinsulin (but not insulin). If the animal is immunized with pure insulin, it would soon become sick and die. Each rabbit was hypodermically injected with 600 mg antigen mixed with complete Freund’s adjuvant the first time, and then boosted three times with 300 mg antigen mixed with incomplete Freund’s adjuvant. The injection interval was 2 weeks. Seven days after the last immunization, the serum of the immunized animals was collected. The anti-insulin polyclonal antibodies (pAbs) in the antiserum were purified by affinity chromatography using recombinant insulin (purchased from Novo Nordisk, Bagsvaerd, Denmark) coupled CNBr-activated Sepharose (GE Healthcare). The titer of the anti-insulin pAbs was assayed by indirect ELISA. Microtiter plates (Coring, New York, USA) were coated with 20 mg anti-insulin pAbs, and then blocked with 1% bovine serum albumin (BSA) overnight at 48C. The samples (proinsulin, insulin, and 55-peptide) were added to each well, respectively. The plate was incubated for 90 min at 378C and washed three times with PBST (10 mM PBS þ 0.05% Tween-20). Anti-55-peptide mAbs were added and incubated for 90 min at 378C. The plate was washed three times with PBST and then incubated with horse radish peroxidase (HRP)-conjugated goat anti-mouse IgG for 90 min at 378C. After washing, tetramethylbenzidine solution was added into wells and incubated for 10–15 min. Finally, 100 ml of 2 M H2SO4 solution was added to terminate the reaction. The absorbance was read at dual filter 450/620 nm. The anti-insulin pAbs were efficiently purified with affinity chromatography, and the antibody heavy chains and light chains could be detected by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) [Fig. 1(A)]. The titer for the anti-insulin pAbs was 1 : 32,000 as determined by indirect ELISA [Fig. 1(C)]. The anti-55-peptide mAbs were purified by protein-G Sepharose and both the heavy and light chains of the antibody were detected by SDS-PAGE [Fig. 1(B)]. The titer was 1 : 32,000 [Fig. 1(D)]. Acta Biochim Biophys Sin 2013, 45: 704–705 | a The Author 2013. Published by ABBS Editorial Office in association with Oxford University Press on behalf of the Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences. DOI: 10.1093/abbs/gmt041. Advance Access Publication 23 April 2013

Comparative studies on intermediary metabolism and hormonal counterregulation following human insulin (recombinant DNA) and purified pork insulin in man

Comparison of the Effect of Semisynthetic Human Insulin and Porcine Insulin on Glucose Kinetics, Plasma Free Fatty Acid and Amino Acid Levels in Man

Pharmacokinetics and Pharmacodynamics of 40/60 Premixed Recombinant Human Insulin Injection Preparations

Differences in bioactivity between human insulin and insulin analogues approved for therapeutic use- compilation of reports from the past 20 years

Pharmacokinetics, Pharmacodynamics, and Bioequivalence Study of SciLin TMR Recombinant Human Insulin Injection Preparation

Effect of pegylation recombinant human growth hormone on secretion function of pancreas islet in hypophysectomized rats and its mechanism

Differential Effects of IGF-I and Insulin on Glucoregulation and Fat Metabolism in Depancreatized Dogs

Comparison of sub-chronic metabolic effects of stable forms of naturally occurring GIP(1-30) and GIP(1-42) in high-fat fed mice.

[A Study on the Feasibility to Assay Minipig Insulin Through Human Insulin Radioimmunoassay Kit].

Effects of Insulin on Rat Anterior Pituitary Cells: Inhibition of Growth Hormone Secretion and mRNA Levels

Human Insulin Versus Porcine Insulin in Rhesus Monkeys with Diabetes Mellitus

Preparation and Pharmacodynamics Study of a Novel Rapid-Acting An-alog of Human Insulin

Efficacy and Safety of Isophane Protamine Insulin Injection 30R to Isophane Protamine Biosynthetic Human Insulin Injection 30R in Type 2 Diabetics Poorly Controlled with Oral Hypoglycemic Agents

Dose-response characteristics for effects of insulin on production and utilization of glucose in man

Comparison of the Effect Between Insulin Lispro 75/25 and Humulin 70/30 on the Postprandial Blood Glucose Excursion in Patients with Diabetes

Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers

Monoclonal and Polyclonal Antibodies Against the Precursor of Recombinant Human Insulin

Bioequivalence Between Two Human Insulin Analogs in Chinese Population: Glulisine and Lispro

Comparative Effects of GLP-1 and GLP-2 on Beta-Cell Function, Glucose Homeostasis and Appetite Regulation

Efficacy and immunogenicity of insulin biosimilar compared to their reference products: a systematic review and meta-analysis

Evaluation of Insulin Lispro and Biosynthetic Human Insulin in Pulmonary Absorption: in Vivo and in Vitro Studies.